A detailed history of Hudson Bay Capital Management LP transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Hudson Bay Capital Management LP holds 135,000 shares of IOVA stock, worth $1.05 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
135,000
Previous 250,000 46.0%
Holding current value
$1.05 Million
Previous $2.01 Million 36.81%
% of portfolio
0.01%
Previous 0.01%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$7.28 - $11.9 $837,200 - $1.37 Million
-115,000 Reduced 46.0%
135,000 $1.27 Million
Q2 2024

Aug 14, 2024

BUY
$7.78 - $14.19 $1.56 Million - $2.84 Million
200,000 Added 400.0%
250,000 $2.01 Million
Q1 2024

May 15, 2024

SELL
$7.59 - $17.47 $1.71 Million - $3.93 Million
-225,000 Reduced 81.82%
50,000 $741,000
Q4 2023

Feb 14, 2024

SELL
$3.3 - $8.89 $512,160 - $1.38 Million
-155,200 Reduced 36.08%
275,000 $2.24 Million
Q3 2023

Nov 14, 2023

BUY
$4.44 - $8.79 $689,088 - $1.36 Million
155,200 Added 56.44%
430,200 $1.96 Million
Q2 2023

Aug 14, 2023

SELL
$5.36 - $9.06 $1.17 Million - $1.98 Million
-218,553 Reduced 44.28%
275,000 $1.94 Million
Q1 2023

May 15, 2023

BUY
$5.53 - $8.22 $1.03 Million - $1.53 Million
185,553 Added 60.24%
493,553 $3.02 Million
Q4 2022

Feb 14, 2023

BUY
$5.62 - $10.0 $1.17 Million - $2.08 Million
208,000 Added 208.0%
308,000 $1.97 Million
Q2 2022

Aug 12, 2022

BUY
$6.38 - $18.33 $478,500 - $1.37 Million
75,000 Added 300.0%
100,000 $1.1 Million
Q1 2022

May 16, 2022

BUY
$12.38 - $19.1 $309,500 - $477,500
25,000 New
25,000 $416,000

Others Institutions Holding IOVA

About IOVANCE BIOTHERAPEUTICS, INC.


  • Ticker IOVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 157,800,992
  • Market Cap $1.23B
  • Description
  • Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...
More about IOVA
Track This Portfolio

Track Hudson Bay Capital Management LP Portfolio

Follow Hudson Bay Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hudson Bay Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Hudson Bay Capital Management LP with notifications on news.